Comparison of CL Wear Between Two Allergy Drops

This study is not yet open for participant recruitment.

Verified by Hom, Milton M., OD, FAAO, June 2007

First Received: June 19, 2007 Last Updated: June 20, 2007 History of Changes

Sponsors and Collaborators:	Hom, Milton M., OD, FAAO Inspire Pharmaceuticals
Information provided by:	Hom, Milton M., OD, FAAO
ClinicalTrials.gov Identifier:	NCT00489398

Purpose

Comparison of two allergy drops for enhancing comfort and performance of contact lens wear

Condition	Intervention	Phase
Allergic Conjunctivitis	Drug: epinastine HCL and olopatadine HCL	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Active Control, Crossover Assignment, Efficacy Study
Official Title:	Comparison of CL Wear Between Epinastine Hydrochloride and Olopatadine Hydrochloride

Resource links provided by NLM:

MedlinePlus related topics: Allergy Eye Wear Pinkeye

Drug Information available for: Epinastine Epinastine hydrochloride Olopatadine Patanol

U.S. FDA Resources

Further study details as provided by Hom, Milton M., OD, FAAO:

Primary Outcome Measures:

Contact lens objective and subjective clinical performance testing [ Time Frame: up to 3 months ]

Estimated Enrollment:	25
Study Start Date:	July 2007
Estimated Study Completion Date:	December 2007

Detailed Description:

Contact lens patients will instill allergy drops and subjective and objective tests will be performed

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Males or females > 18 years old
Mild to moderate dry eye symptoms
Likely to complete all study visits and able to provide informed consent

Exclusion Criteria:

Current use of topical cyclosporine
Known contraindications to any study medication or ingredients
Active ocular diseases or uncontrolled systemic disease (blepharitis patients that are actively being treated or disease that is uncontrollable)
Ocular surgery within the past 3 months

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00489398

Contacts

Contact: Milton M Hom, OD FAAO

6269637100

eyemage@mminternet.com

Locations

United States, California
Milton M. Hom, OD, FAAO.
Azusa, California, United States, 91702-2740

Sponsors and Collaborators

Hom, Milton M., OD, FAAO

Inspire Pharmaceuticals

Investigators

Study Director:

Milton M Hom, OD FAAO

Private Practice

More Information

No publications provided

Study ID Numbers:	5316
Study First Received:	June 19, 2007
Last Updated:	June 20, 2007
ClinicalTrials.gov Identifier:	NCT00489398 History of Changes
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Anti-Inflammatory Agents
Neurotransmitter Agents
Conjunctivitis, Allergic
Eye Diseases
Anti-Allergic Agents
Conjunctivitis
Olopatadine
Conjunctival Diseases
Histamine
Naphazoline
Hypersensitivity
Histamine Antagonists

Analgesics, Non-Narcotic
Guaifenesin
Hypersensitivity, Immediate
Histamine phosphate
Histamine H1 Antagonists
Anti-Inflammatory Agents, Non-Steroidal
Peripheral Nervous System Agents
Analgesics
Phenylpropanolamine
Antirheumatic Agents
Epinastine

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Hypersensitivity
Sensory System Agents
Therapeutic Uses
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Immune System Diseases
Conjunctivitis, Allergic
Eye Diseases
Histamine Agents
Conjunctivitis

Anti-Allergic Agents
Olopatadine
Conjunctival Diseases
Pharmacologic Actions
Histamine Antagonists
Analgesics, Non-Narcotic
Hypersensitivity, Immediate
Histamine H1 Antagonists
Peripheral Nervous System Agents
Antirheumatic Agents
Histamine H1 Antagonists, Non-Sedating
Central Nervous System Agents
Epinastine

ClinicalTrials.gov processed this record on July 02, 2009